Literature DB >> 27595288

Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections.

R V Raj1, P Hari1, M Pasquini1, N Epperla1, A D'Souza1, T Fenske1, B E Shaw1, J D Rizzo1, W Drobyski1, M Hamadani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27595288     DOI： 10.1038/bmt.2016.216

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

Review 1.  Cyclophosphamide-induced immunological tolerance: an overview.

Authors:  H Mayumi; M Umesue; K Nomoto
Journal:  Immunobiology       Date:  1996-07       Impact factor: 3.144

2.  Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.

Authors:  Scott R Solomon; Connie A Sizemore; Melissa Sanacore; Xu Zhang; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

3.  Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.

Authors:  P V O'Donnell; L Luznik; R J Jones; G B Vogelsang; M S Leffell; M Phelps; P Rhubart; K Cowan; S Piantados; E J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

4.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

5.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

Authors:  E B Papadopoulos; M Ladanyi; D Emanuel; S Mackinnon; F Boulad; M H Carabasi; H Castro-Malaspina; B H Childs; A P Gillio; T N Small
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

6.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

7.  Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.

Authors:  Scott R Solomon; Connie A Sizemore; Melissa Sanacore; Xu Zhang; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-01       Impact factor: 5.742

8.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

9.  Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Rima M Saliba; Ulas D Bayraktar; Ying Jiang; Roland Bassett; Sa A Wang; Marina Konopleva; Marcelo Fernandez-Vina; Nivia Montes; Doyle Bosque; Julianne Chen; Gabriela Rondon; Gheath Alatrash; Amin Alousi; Qaiser Bashir; Martin Korbling; Muzaffar Qazilbash; Simrit Parmar; Elizabeth Shpall; Yago Nieto; Chitra Hosing; Partow Kebriaei; Issa Khouri; Uday Popat; Marcos de Lima; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-11       Impact factor: 5.742

10.  Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Authors:  R Crocchiolo; S Bramanti; A Vai; B Sarina; R Mineri; E Casari; F Tordato; E Mauro; I Timofeeva; E Lugli; D Mavilio; C Carlo-Stella; A Santoro; L Castagna
Journal:  Transpl Infect Dis       Date:  2015-04       Impact factor: 2.228
  10 in total
  2 in total

1.  Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.

Authors:  Yuhua Ru; Jinjin Zhu; Tiemei Song; Yiyang Ding; Ziling Zhu; Yi Fan; Yang Xu; Aining Sun; Huiying Qiu; Zhengming Jin; Xiaowen Tang; Yue Han; Chengcheng Fu; Suning Chen; Xiao Ma; Feng Chen; Jia Chen; Depei Wu
Journal:  Front Cell Infect Microbiol       Date:  2022-05-16       Impact factor: 6.073

Review 2.  CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update.

Authors:  Xiao-Hua Luo; Yan Zhu; Yu-Ting Chen; Li-Ping Shui; Lin Liu
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.